What's new in systemic therapy for endometrial cancer

Abstract

Purpose of review: Endometrial cancer is one of the most common gynecologic cancers. Most women present with early disease that is curable. In women with poor prognostic factors or advanced disease, survival is greatly diminished. Recently there have been several trials of adjuvant treatment and treatment for advanced and recurrent endometrial cancer. These trials of systemic therapy will be reviewed.

Recent findings: Several areas have been the focus of recent literature on systemic therapy for endometrial cancer. These include large phase III trials of multi-agent chemotherapy regimens for advanced and recurrent endometrial cancer, combined chemotherapy and radiotherapy treatments, and novel targeted agents.

Summary: New approaches to combining the traditional adjuvant modalities for high-risk endometrial cancer as well as combining new novel agents with traditional chemotherapeutics will improve patient outcomes.